Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT04308031

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Chun-Yao Huang (from the registry)
Registry
  • NCT NCT04308031
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04308031. Randomized; no masking; primary purpose treatment. Start 2018-08-26 (actual); primary completion 2020-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction
Condition
Ivabradine
Condition
Heart Failure
Intervention (Drug)
Ivabradine 5 mg [Corlanor]
Intervention (Drug)
Digoxin 0.25 mg
Lead sponsor
Chun-Yao Huang (class: other)

Record details

Record id
cardio:ct-nct04308031
Content hash
d311bab402cd5df2815f05478785645af3776fc3d422c789014ae2ba4406170e